1-(tetrahydro-2H-pyran-4-yl)guanidine hydrochloride | 1447606-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 1-(tetrahydro-2H-pyran-4-yl)guanidine hydrochloride
• 英文别名: 1-(Oxan-4-yl)guanidine hydrochloride；2-(oxan-4-yl)guanidine;hydrochloride
• CAS: 1447606-48-5
• 化学式: C₆H₁₃N₃O*(x)ClH
• mdl: MFCD25970409
• 分子量: 179.65
• InChiKey: ZZFHEGWAVVSXKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.0
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  73.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 4-(3-(dimethylamino)-2-methylacryloyl)-1-tosyl-1H-pyrrole-2-carboxylate 、 1-(tetrahydro-2H-pyran-4-yl)guanidine hydrochloride 在 N,N-二异丙基乙胺 作用下， 以 甲苯 为溶剂， 反应 20.0h， 以18 g的产率得到methyl 4-(5-methyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1-tosyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS FOR TREATING PSORIASIS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT DU PSORIASIS

  摘要：

  本文揭示了一种治疗牛皮癣的方法，涉及使用化合物I的公式和/或其药用可接受的盐。

  公开号：

  WO2016192064A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS COMME INHIBITEURS D'ERK
  申请人：CHANGZHOU JIEKAI PHARMATECH CO LTD

  公开号：WO2016192063A1

  公开（公告）日：2016-12-08

  Disclosed herein is a compound of formula (I) and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors. They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I) and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

  本文披露了一种化合物(I)及/或其药用可接受的盐，可作为Erk抑制剂。它们在治疗通过抑制Erk可治疗的疾病，如癌症方面有潜在用途。本文还披露了一种包含化合物(I)及/或其药用可接受的盐和药用可接受的载体的药物组合物。
• Heterocyclic compounds for treating psoriasis
  申请人：JS INNOPHARM (SHANGHAI LTD.)

  公开号：US10238657B2

  公开（公告）日：2019-03-26

  Disclosed herein is a method of treating psoriasis involving the use of compound of formula I and/or a pharmaceutically acceptable salt thereof.

  本文公开了一种治疗银屑病的方法，涉及使用式 I 化合物和/或其药学上可接受的盐。
• Heterocyclic compounds as ERK inhibitors
  申请人：CHANGZHOU JIEKAI PHARMATECH CO. LTD

  公开号：US10479791B2

  公开（公告）日：2019-11-19

  Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

  本文公开了一种可作为 Erk 抑制剂的式 I 化合物和/或其药学上可接受的盐： 它们可用于治疗可通过抑制 Erk 治疗的疾病，如癌症。本文还公开了一种药物组合物，它包含式 I 化合物和/或其药学上可接受的盐以及药学上可接受的载体。
• HETEROCYCLIC COMPOUNDS FOR TREATING PSORIASIS
  申请人：JS Innopharm (Shanghai) Ltd.

  公开号：EP3303335A1

  公开（公告）日：2018-04-11
• HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS
  申请人：CHANGZHOU JIEKAI PHARMATECH CO. LTD

  公开号：US20180179211A1

  公开（公告）日：2018-06-28

  Disclosed herein is a compound of formula I and/or a pharmaceutically acceptable salt thereof that can serve as Erk inhibitors: They are potentially useful in the treatment of diseases treatable by inhibition of Erk, such as cancers. Also disclosed herein is a pharmaceutical composition comprising a compound of formula I and/or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.